These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 2547468)

  • 21. Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis.
    Koelewijn JM; de Haas M; Vrijkotte TG; van der Schoot CE; Bonsel GJ
    BJOG; 2009 Sep; 116(10):1307-14. PubMed ID: 19538414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Guideline for prevention of RhD alloimmunizationin RhD negative women].
    Lubušký M; Procházka M; Simetka O; Holusková I
    Ceska Gynekol; 2013 Apr; 78(2):132-3. PubMed ID: 23710977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Controversies in Rh prophylaxis. Who needs Rh immune globulin and when should it be given?
    Bowman JM
    Am J Obstet Gynecol; 1985 Feb; 151(3):289-94. PubMed ID: 2982267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland.
    Haimila K; Sulin K; Kuosmanen M; Sareneva I; Korhonen A; Natunen S; Tuimala J; Sainio S
    Acta Obstet Gynecol Scand; 2017 Oct; 96(10):1228-1233. PubMed ID: 28718198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preventing Rhesus D haemolytic disease of the newborn by giving anti-D immunoglobulin: are the guidelines being adequately followed?
    Howard HL; Martlew VJ; McFadyen IR; Clarke CA
    Br J Obstet Gynaecol; 1997 Jan; 104(1):37-41. PubMed ID: 8988694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consequences of being Rhesus D immunized during pregnancy and how to optimize new prevention strategies.
    Tiblad E; Westgren M; Pasupathy D; Karlsson A; Wikman AT
    Acta Obstet Gynecol Scand; 2013 Sep; 92(9):1079-85. PubMed ID: 23750781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo studies of monoclonal anti-D and the mechanism of immune suppression.
    Kumpel BM
    Transfus Clin Biol; 2002 Jan; 9(1):9-14. PubMed ID: 11889904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time points and risk factors for RhD immunizations after the implementation of targeted routine antenatal anti-D prophylaxis: A retrospective nationwide cohort study.
    Jernman R; Isaksson C; Haimila K; Kuosmanen M; Mäkikallio-Anttila K; Toivonen S; Ordén MR; Sulin K; Tihtonen K; Vääräsmäki M; Sainio S
    Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1868-1875. PubMed ID: 34157128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Advantages of preventing Rh isoimmunization].
    Mikulandra F; Merlak I; Perisa M; Kapitanović Z; Barbetti V; Kimer M; Glavadanović N
    Jugosl Ginekol Perinatol; 1985; 25(1-2):29-34. PubMed ID: 3003466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal anti-D development programme.
    Kumpel BM
    Transpl Immunol; 2002 Aug; 10(2-3):199-204. PubMed ID: 12216950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis.
    Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S
    BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Following targeted routine antenatal anti-D prophylaxis, almost half of the pregnant women had undetectable anti-D prophylaxis at delivery.
    Sørensen K; Stjern HE; Karlsen BAG; Tomter G; Ystad I; Herud I; Baevre MS; Llohn AH; Akkök ÇA
    Acta Obstet Gynecol Scand; 2022 Apr; 101(4):431-440. PubMed ID: 35224728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prevention of fetomaternal rhesus-D allo-immunization. Practical aspects].
    Cortey A; Brossard Y
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S123-1S130. PubMed ID: 16495838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rh isoimmunization during pregnancy: antenatal prophylaxis.
    Bowman JM; Chown B; Lewis M; Pollock JM
    Can Med Assoc J; 1978 Mar; 118(6):623-7. PubMed ID: 77714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prevention of Rh (D) alloimmunization in Rh (D) negative women in pregnancy and after birth of Rh (D) positive infant].
    L'ubuský M; Procházka M; Krejcová L; Vetr M; Santavý J; Kudela M
    Ceska Gynekol; 2006 May; 71(3):173-9. PubMed ID: 16768042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Why women are not receiving anti-Rh prophylaxis.
    Tovey LA
    Br Med J (Clin Res Ed); 1987 Feb; 294(6570):508. PubMed ID: 3030482
    [No Abstract]   [Full Text] [Related]  

  • 37. ACOG releases report on prevention of D isoimmunization.
    Am Fam Physician; 1991 Jan; 43(1):307-8, 310. PubMed ID: 1846056
    [No Abstract]   [Full Text] [Related]  

  • 38. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy.
    Koelewijn JM; de Haas M; Vrijkotte TG; Bonsel GJ; van der Schoot CE
    Transfusion; 2008 Aug; 48(8):1721-9. PubMed ID: 18507749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should anti-D immunoglobulin be given antenatally?
    Tovey GH
    Lancet; 1980 Aug; 2(8192):466-8. PubMed ID: 6106109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case for the antenatal administration of anti-D immunoglobulin to primigravidae.
    Tovey LA; Taverner JM
    Lancet; 1981 Apr; 1(8225):878-81. PubMed ID: 6112301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.